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How can we be sure that renal
dysfunction after coronary
angiography is just explained
by contrast nephropathy?
To the Editor: A review has been performed on the
very hot topic of the role of N-acetylcysteine (NAC) on
contrast nephropathy (CN) [1], of great clinical impact as
a result of the CN-linked role in worsening prognosis and
increasing costs. The authors wrote that they “assess the
efficacy of NAC for preventing CN after . . . intravenous
contrast media,” and concluded that “NAC may reduce
the incidence of increased creatinine after administration
of intravenous contrast, but this was of borderline statis-
tical significance.” However, both sentences are wrong
and misleading, as are similar conclusions reached by
another meta-analysis [2], because all 15 [1] or 16 [2]
reviewed papers regarded coronary angiography (CA),
except one [3]. First of all, to perform CA, contrast me-
dia are introduced into the arterial vascular bed, and
not intravenously, as when performing computed to-
mography (CT). Second, mechanisms of renal dysfunc-
tion after CA are not only caused by CN, but also by
other causes such as, for instance, cholesterol crystal
embolization.
We suggest that: (1) further studies be analyzed by
separating prevention strategies for CT from those for
CA; (2) for CA, attempts will be made to dissect other
causes of renal damage by looking for the blue toes
syndrome or eosinophilia, in order to exclude choles-
terol embolization; (3) even urea increase was consid-
ered as end point, to avoid the possibility that creatinine
changes might be resulting simply from a direct effect of
NAC [4].
The only quoted paper regarding the use of NAC be-
fore performing CT did demonstrate a protection, by also
using urea values as end point [3].
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Reply from the Authors
We thank Dr. Canavese et al for their letter. We
agree that the term “intravenous contrast administra-
tion” may have been misleading. Perhaps the term
“parenteral contrast administration” would have been
preferable.
As we mentioned in our article, atheroemboli might
explain why NAC seemed to be less efficacious than
computed tomography in the context of coronary
angiography. For this reason we performed subgroup
analysis including only trials of patients undergoing coro-
nary angiography. Although “looking for blue toes or
eosinophilia” has theoretical appeal, we are uncertain
how helpful this would be, because such findings may
take weeks to appear [1], and clinically silent cholesterol
embolization after invasive procedures appears to be
common [2].
The suggestion to use serum urea rather than creati-
nine as an outcome measure seems to miss one of the
main points of our article—that data on costs or clini-
cally relevant outcomes such as death or hospitalization
(and not surrogates such as estimated kidney function)
are needed.
After reading their letter carefully, we are uncertain
whether Dr. Canavese et al feel that our conclusions are
